PE20242356A1 - Composiciones moduladoras de angiotensinogeno y metodos de utilizacion de estas - Google Patents
Composiciones moduladoras de angiotensinogeno y metodos de utilizacion de estasInfo
- Publication number
- PE20242356A1 PE20242356A1 PE2024002116A PE2024002116A PE20242356A1 PE 20242356 A1 PE20242356 A1 PE 20242356A1 PE 2024002116 A PE2024002116 A PE 2024002116A PE 2024002116 A PE2024002116 A PE 2024002116A PE 20242356 A1 PE20242356 A1 PE 20242356A1
- Authority
- PE
- Peru
- Prior art keywords
- angiotensinogen
- agt
- methods
- modulating
- modulating compositions
- Prior art date
Links
- 102000004881 Angiotensinogen Human genes 0.000 title abstract 5
- 108090001067 Angiotensinogen Proteins 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 125000003835 nucleoside group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/15—Peptidyl-dipeptidases (3.4.15)
- C12Y304/15001—Peptidyl-dipeptidase A (3.4.15.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C12N2310/3125—Methylphosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263326733P | 2022-04-01 | 2022-04-01 | |
| US202263407071P | 2022-09-15 | 2022-09-15 | |
| PCT/US2023/017185 WO2023192630A2 (en) | 2022-04-01 | 2023-03-31 | Angiotensinogen-modulating compositions and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20242356A1 true PE20242356A1 (es) | 2024-12-16 |
Family
ID=88203363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024002116A PE20242356A1 (es) | 2022-04-01 | 2023-03-31 | Composiciones moduladoras de angiotensinogeno y metodos de utilizacion de estas |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20240041913A1 (enExample) |
| EP (1) | EP4504937A2 (enExample) |
| JP (1) | JP2025511183A (enExample) |
| KR (1) | KR20240168424A (enExample) |
| CN (1) | CN119137272A (enExample) |
| AU (1) | AU2023245480A1 (enExample) |
| CA (1) | CA3255793A1 (enExample) |
| CL (1) | CL2024002910A1 (enExample) |
| CO (1) | CO2024013353A2 (enExample) |
| IL (1) | IL315862A (enExample) |
| MX (1) | MX2024012080A (enExample) |
| PE (1) | PE20242356A1 (enExample) |
| TW (1) | TW202405171A (enExample) |
| WO (1) | WO2023192630A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240401045A1 (en) | 2021-10-01 | 2024-12-05 | Adarx Pharmaceuticals, Inc. | Angiotensinogen-modulating compositions and methods of use thereof |
| KR20240103025A9 (ko) | 2021-11-16 | 2025-12-10 | 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. | 안지오텐시노겐(agt) 단백질의 발현을 저해하는 조성물 및 방법 |
| WO2026133251A1 (en) | 2024-12-20 | 2026-06-25 | Novartis Ag | Combinations of antisense agents, pharmaceutical compositions and methods of use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005116265A2 (en) * | 2004-05-26 | 2005-12-08 | Wyeth | Probe arrays for expression profiling of rat genes |
| WO2011156734A2 (en) * | 2010-06-11 | 2011-12-15 | Hitachi Chemical Co., Ltd. | Method of characterizing vascular diseases |
| EP3693460A1 (en) * | 2012-07-27 | 2020-08-12 | Ionis Pharmaceuticals, Inc. | Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen |
| TWI851574B (zh) * | 2018-05-14 | 2024-08-11 | 美商阿尼拉製藥公司 | 血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法 |
-
2023
- 2023-03-31 IL IL315862A patent/IL315862A/en unknown
- 2023-03-31 AU AU2023245480A patent/AU2023245480A1/en active Pending
- 2023-03-31 WO PCT/US2023/017185 patent/WO2023192630A2/en not_active Ceased
- 2023-03-31 KR KR1020247036043A patent/KR20240168424A/ko active Pending
- 2023-03-31 CN CN202380037505.2A patent/CN119137272A/zh active Pending
- 2023-03-31 CA CA3255793A patent/CA3255793A1/en active Pending
- 2023-03-31 TW TW112112620A patent/TW202405171A/zh unknown
- 2023-03-31 US US18/194,203 patent/US20240041913A1/en active Pending
- 2023-03-31 EP EP23781897.6A patent/EP4504937A2/en active Pending
- 2023-03-31 JP JP2024558017A patent/JP2025511183A/ja active Pending
- 2023-03-31 PE PE2024002116A patent/PE20242356A1/es unknown
-
2024
- 2024-09-27 CL CL2024002910A patent/CL2024002910A1/es unknown
- 2024-09-30 MX MX2024012080A patent/MX2024012080A/es unknown
- 2024-09-30 CO CONC2024/0013353A patent/CO2024013353A2/es unknown
-
2026
- 2026-03-26 US US19/630,043 patent/US20260224606A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3255793A1 (en) | 2023-10-05 |
| US20240041913A1 (en) | 2024-02-08 |
| WO2023192630A3 (en) | 2024-01-04 |
| CL2024002910A1 (es) | 2025-02-14 |
| WO2023192630A2 (en) | 2023-10-05 |
| CO2024013353A2 (es) | 2024-10-10 |
| JP2025511183A (ja) | 2025-04-15 |
| KR20240168424A (ko) | 2024-11-29 |
| TW202405171A (zh) | 2024-02-01 |
| MX2024012080A (es) | 2024-11-08 |
| EP4504937A2 (en) | 2025-02-12 |
| US20260224606A1 (en) | 2026-08-06 |
| AU2023245480A1 (en) | 2024-10-10 |
| IL315862A (en) | 2024-11-01 |
| CN119137272A (zh) | 2024-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20241340A1 (es) | Composiciones moduladoras de complemento del factor b y metodos de uso de estas | |
| ES2539790T3 (es) | Métodos y composiciones para modular c-met hiperestabilizado | |
| PE20230179A1 (es) | Metodos y composiciones para el tratamiento de un trastorno asociado con angiotensinogeno (agt) | |
| MX2023011794A (es) | Composiciones y métodos para el tratamiento de la proteinopatía de proteina de union a acido desoxirribonucleico tar 43 (tdp-43). | |
| AR054148A1 (es) | Secuencias de nucleotidos que median en la fertilidad masculina de las plantas y metodo para usarlas | |
| ES2542853T3 (es) | Método para tratar miastenia grave | |
| BR112022023025A2 (pt) | Moduladores de htt para tratar doença de huntington | |
| AR115416A1 (es) | Moduladores de la expresión de apol1 | |
| AR106135A1 (es) | Moduladores de la expresión del sarcoma de la rata de kirsten (kras) | |
| AR083957A1 (es) | Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica | |
| CO2024017547A2 (es) | Compuestos para tratar la ataxia espinocerebelosa tipo 3 | |
| ES2689746T3 (es) | Anticuerpos monoclonales contra la claudina-18 para el tratamiento de cáncer | |
| ECSP066421A (es) | MODULACION DE LA EXPRESION DE eIF4E | |
| AR069821A1 (es) | Composiciones y metodos de uso de la interferencia de arn para el control de nematodos | |
| AR055169A1 (es) | Metodos para el control genetico de infestaciones de insectos en plantas y composiciones para los mismos | |
| GT200800158A (es) | Pirazolquinolonas como potentes inhibidores de parp | |
| NO20081975L (no) | Diarylamin-inneholdende forbindelser og sammensetninger, og deres anvendelse som modulatorer av C-kit-reseptorer | |
| AR030961A1 (es) | Secuencias de nucleotidos que intervienen en la fertilidad masculina en plantas y metodo de uso de las mismas | |
| CU23784B7 (es) | Bencimidazoles sustituidos como inhibidores de cinasa | |
| PE20211065A1 (es) | Metodo para tratar la epilepsia | |
| CL2025002127A1 (es) | Variantes de mb2cas12a con eficiencia mejorada. | |
| AR047574A1 (es) | Genes del ciclo celular y metodos de uso relacionados | |
| CO2024010542A2 (es) | Inhibidores de apol1 y métodos de uso | |
| MX373950B (es) | USO DE UN INHIBIDOR TEMPORAL DE UN GEN p53 PARA LA PROFILAXIS DE LESIÓN POR ISQUEMIA-REPERFUSIÓN. | |
| MX2021009454A (es) | Purificacion de analogos de glp-1. |